company background image
4536 logo

Santen Pharmaceutical TSE:4536 Stock Report

Last Price

JP¥1.79k

Market Cap

JP¥632.1b

7D

-0.9%

1Y

47.7%

Updated

24 Jul, 2024

Data

Company Financials +

Santen Pharmaceutical Co., Ltd.

TSE:4536 Stock Report

Market Cap: JP¥632.1b

4536 Stock Overview

Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally.

4536 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance1/6
Financial Health5/6
Dividends5/6

Santen Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Santen Pharmaceutical
Historical stock prices
Current Share PriceJP¥1,790.50
52 Week HighJP¥1,859.50
52 Week LowJP¥1,196.50
Beta0.20
11 Month Change10.29%
3 Month Change20.05%
1 Year Change47.73%
33 Year Change18.03%
5 Year Change1.68%
Change since IPO478.83%

Recent News & Updates

Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Jun 25
Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

May 11
Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Jun 25
Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares

Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

May 11
Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?

May 08
Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?

Shareholder Returns

4536JP PharmaceuticalsJP Market
7D-0.9%0.4%-2.3%
1Y47.7%18.3%21.1%

Return vs Industry: 4536 exceeded the JP Pharmaceuticals industry which returned 18.3% over the past year.

Return vs Market: 4536 exceeded the JP Market which returned 21.1% over the past year.

Price Volatility

Is 4536's price volatile compared to industry and market?
4536 volatility
4536 Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement3.9%
Market Average Movement3.7%
10% most volatile stocks in JP Market7.3%
10% least volatile stocks in JP Market1.8%

Stable Share Price: 4536 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4536's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18903,744Takeshi Itowww.santen.com

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.

Santen Pharmaceutical Co., Ltd. Fundamentals Summary

How do Santen Pharmaceutical's earnings and revenue compare to its market cap?
4536 fundamental statistics
Market capJP¥632.09b
Earnings (TTM)JP¥26.63b
Revenue (TTM)JP¥301.97b

23.7x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4536 income statement (TTM)
RevenueJP¥301.97b
Cost of RevenueJP¥123.26b
Gross ProfitJP¥178.71b
Other ExpensesJP¥152.08b
EarningsJP¥26.63b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 06, 2024

Earnings per share (EPS)75.45
Gross Margin59.18%
Net Profit Margin8.82%
Debt/Equity Ratio8.8%

How did 4536 perform over the long term?

See historical performance and comparison

Dividends

1.9%

Current Dividend Yield

45%

Payout Ratio

Does 4536 pay a reliable dividends?

See 4536 dividend history and benchmarks
When do you need to buy 4536 by to receive an upcoming dividend?
Santen Pharmaceutical dividend dates
Ex Dividend DateSep 27 2024
Dividend Pay DateDec 02 2024
Days until Ex dividend64 days
Days until Dividend pay date130 days

Does 4536 pay a reliable dividends?

See 4536 dividend history and benchmarks
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.